secwatch.observer — SEC 8-K summary
======================================

Issuer:     QSAM Biosciences, Inc. (—)
CIK:        0001310527
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001493152-24-017523
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

QSAM Biosciences acquired by Telix; shareholders get 1,744 Telix shares + 2,000 CVRs per share
--------------------------------------------------------------------------------

- Merger completed May 2, 2024; each QSAM share converted into 1,744 Telix ordinary shares and 2,000 contingent value rights (CVRs).
- Total cash consideration approximately $33.1M (net of adjustments) plus up to $90M in contingent milestone payments via CVRs.
- All directors and officers resigned; Kevin Richardson and Darren Smith named directors of surviving corporation Telix QSAM, Inc.
- QSAM's common stock to cease trading on OTCQB approximately May 3, 2024, following FINRA corporate action.
- Company renamed Telix QSAM, Inc. under amended and restated certificate of incorporation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1310527/000149315224017523/0001493152-24-017523-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1310527/000149315224017523/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-017523

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer